Open-label, Randomized, Single-dose, Cross-over Study to Assess Bioequivalence Between a Single 120 mg Nifurtimox Tablet and a Newly Developed 120 mg Nifurtimox Tablet, Administered Orally Under Fed Conditions to Adult Male and Female Patients With Chronic Chagas' Disease
Phase of Trial: Phase I
Latest Information Update: 30 Jan 2019
At a glance
- Drugs Nifurtimox (Primary)
- Indications Chagas disease
- Focus Pharmacokinetics
- Sponsors Bayer
- 23 Jan 2019 Planned End Date changed from 30 Apr 2019 to 21 Jun 2019.
- 23 Jan 2019 Planned primary completion date changed from 27 Mar 2019 to 29 Mar 2019.
- 23 Jan 2019 Status changed from not yet recruiting to recruiting.